Company intelligence / Profile preview

RediMendMD

Sarasota, Florida, United States

Ownership: Private
Development stage: Other

Overview

RediMend was a medical device company focused on the development of collagen-based implants for surgical applications. The company's primary product, also named RediMend, is a collagen dural graft used in neurosurgery to repair or replace the dural membrane. The technology utilizes a highly purified Type I collagen matrix derived from bovine Achilles tendon, designed to provide a scaffold for tissue ingrowth while maintaining a liquid-tight seal. In 2004, the company's assets and technology were acquired by Integra LifeSciences, which continues to market the product as part of its neurosurgical portfolio.

Therapeutic areas: Neurology
Modalities: BiologicDevice
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on RediMendMD.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RediMendMD.

Explore the full profile